Table 2.
Multivariate analysis of transplant outcomes
| Outcome | HR (95% CI) | p | |
|---|---|---|---|
| RI | Secondary AML vs de novo AML | 1.3 (1.02‐1.5) | 0.03 |
| Good risk (reference) | 1 | ||
| Intermediate risk | 1.2 (0.8‐1.8) | 0.4 | |
| Poor risk | 2.2 (1.45‐3.31) | <0.001 | |
| MSD (reference) | 1 | ||
| UD 10/10 | 0.8 (0.698‐1.02) | 0.09 | |
| UD 9/10 | 1.1 (0.854‐1.52) | 0.4 | |
| Haplo | 0.9 (0.602‐1.25) | 0.4 | |
| CB | 0.7 (0.436‐1.14) | 0.2 | |
| NRM | Age (per 10 years) | 1.3 (1.17‐1.41) | <0.001 |
| Secondary AML vs de novo AML | 1.4 (1.13‐1.77) | 0.002 | |
| KPS =80% vs <80% | 0.6 (0.479‐0.752) | <0.001 | |
| MSD (reference) | |||
| UD 10/10 | 1.4 (1.1‐1.79) | 0.006 | |
| UD 9/10 | 2.4 (1.75‐3.28) | <0.001 | |
| Haplo | 1.8 (1.2‐2.57) | 0.004 | |
| CB | 2.04 (1.32‐3.16) | 0.001 | |
| Female vs male patient | 0.8 (0.647‐0.937) | 0.008 | |
| Patient CMV positive serology | 1.3 (1.01‐1.55) | 0.04 | |
| LFS | Age (per 10 years) | 1.1 (1.03‐1.16) | 0.002 |
| Secondary AML vs de novo AML | 1.3 (1.14‐1.53) | <0.001 | |
| Good risk (reference) | |||
| Intermediate risk | 1.2 (0.857‐1.56) | 0.3 | |
| Poor risk | 1.8 (1.31‐2.42) | <0.001 | |
| KPS =80% vs <80% | 0.7 (0.636‐0.867) | <0.001 | |
| MSD (reference) | |||
| UD 10/10 | 1.03 (0.888‐1.2) | 0.7 | |
| UD 9/10 | 1.6 (1.26‐1.92) | <0.001 | |
| Haplo | 1.2 (0.909‐1.53) | 0.2 | |
| CB | 1. (0.831‐1.58) | 0.4 | |
| OS | Age (per 10 years) | 1.2 (1.1‐1.24) | <0.001 |
| Secondary AML vs de novo AML | 1.3 (1.12‐1.54) | <0.001 | |
| Good risk (reference) | |||
| Intermediate risk | 1.1 (0.815‐1.57) | 0.5 | |
| Poor risk | 1.7 (1.21‐2.36) | 0.002 | |
| KPS =80% vs <80% | 0.7 (0.564‐0.779) | <0.001 | |
| MSD (reference) | |||
| UD 10/10 | 1.1 (0.92‐1.27) | 0.3 | |
| UD 9/10 | 1.7 (1.34‐2.1) | <0.001 | |
| Haplo | 1.2 (0.891‐1.58) | 0.2 | |
| CB | 1.2 (0.848‐1.68) | 0.3 | |
| Female vs male patient | 0.9 (0.752‐0.973) | 0.02 | |
| Patient CMV positive serology | 1.2 (0.997‐1.34) | 0.06 | |
| GRFS | Secondary AML vs de novo AML | 1.2 (1.05‐1.39) | 0.007 |
| Good risk (reference) | |||
| Intermediate risk | 1.3 (0.986‐1.67) | 0.06 | |
| Poor risk | 1.8 (1.36‐2.36) | <0.001 | |
| KPS =80% vs <80% | 0.8 (0.712‐0.947) | 0.006 | |
| MSD (reference) | |||
| UD 10/10 | 1.2 (1.01‐1.32) | 0.03 | |
| UD 9/10 | 1.5 (1.26‐1.86) | <0.001 | |
| Female vs male patient | 0.85 (0.762‐0.94) | 0.002 | |
| Female vs male donor | 1.2 (1.04‐1.29) | 0.006 | |
| ATG used | 0.8 (0.733‐0.926) | 0.001 | |
| aGVHD III‐IV | Good risk (reference) | ||
| Intermediate risk | 2.5 (1.11‐5.73) | 0.03 | |
| Poor risk | 2.3 (0.988‐5.35) | 0.05 | |
| MSD (reference) | |||
| UD 10/10 | 1.8 (1.28‐2.63) | 0.001 | |
| UD 9/10 | 3 (1.85‐4.77) | <0.001 | |
| Haplo | 2.6 (1.58‐4.32) | <0.001 | |
| CB | 3.7 (2.17‐6.36) | <0.001 | |
| Female vs male donor | 1.4 (1.04‐1.78) | 0.03 | |
| ATG used | 0.6 (0.441‐0.802) | <0.001 | |
| Patient CMV positive serology | 0.7 (0.541‐0.957) | 0.02 | |
| cGVHD | KPS =80% vs <80% | 0.8 (0.667‐0.988) | 0.04 |
| MSD (reference) | |||
| UD 10/10 | 1.2 (1.03‐1.46) | 0.02 | |
| UD 9/10 | 1.4 (1.02‐1.79) | 0.04 | |
| Haplo | 0.7 (0.523‐1.06) | 0.09 | |
| CB | 0.5 (0.329‐0.818) | 0.004 | |
| Female vs male patient | 0.8 (0.741‐0.973) | 0.02 | |
| Female vs male donor | 1.3 (1.15‐1.52) | <0.001 | |
| ATG used | 0.6 (0.552‐0.75) | <0.001 | |
| Severe cGVHD | MSD (reference) | ||
| UD 10/10 | 1.4 (1.1‐1.83) | 0.007 | |
| UD 9/10 | 1.2 (0.755‐1.83) | 0.5 | |
| Haplo | 0.6 (0.331‐1.02) | 0.06 | |
| CB | 0.3 (0.148‐0.763) | 0.009 | |
| Female vs male patient | 0.7 (0.6‐0.895) | 0.002 | |
| Female vs male donor | 1.6 (1.28‐1.92) | <0.001 | |
| ATG used | 0.5 (0.427‐0.672) | <0.001 | |
Only variables with p values <0.1 were included.
Abbreviations: ATG, anti‐thymocyte globulin; CB, cord blood transplant; CMV, Cytomegalovirus; GRFS, graft‐versus‐host disease‐free, relapse‐free survival; GVHD, graft‐versus‐host disease; Haplo, haploidentical transplant; KPS, Karnofsky performance status; LFS, leukemia‐free survival; MSD, matched sibling donor; NRM, non‐relapse mortality; OS, overall survival; RI, relapse incidence; UD, unrelated donor.